Available immunotherapies such as PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, and immune-checkpoint combination therapies have dramatically improved the condition of patients with breast cancer and the adverse effects of the treatment. This evidence concerns the gene CD274 and breast carcinoma.